Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
RSS SUMMARY · AGGREGATED FROM TWSJ
The German pharmaceutical-and-agricultural group said that the deal aims to complement its ophthalmology pipeline.
The German pharmaceutical-and-agricultural group said that the deal aims to complement its ophthalmology pipeline.
The German pharmaceutical-and-agricultural group said that the deal aims to complement its ophthalmology pipeline.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
World News
Israel Built and Defended a Secret Iran War Base in Iraq
TWSJ·4h ago·3 min read
Tech
For Palantir, AI Is a Product, a Punching Bag—and a Problem
TWSJ·6h ago·3 min read
World News
The Hunter-Gatherers Weighing Whether to Join the Modern World
TWSJ·6h ago·3 min read
Business
Person Struck and Killed by Plane on Runway at Denver Airport
TWSJ·7h ago·3 min read
Related
On this beat
Health
Passengers on Hantavirus Cruise Ship Will Disembark in Tenerife and Return to Home Countries
TNYT·3h ago·3 min read
Health
WHO director says he will personally oversee hantavirus cruise evacuation
CBS NEWS·7h ago·3 min read
Health
Hantavirus Vaccines and Treatments Are in the Pipeline
TNYT·8h ago·3 min read
Health
If you find yourself walking more slowly than you used to, it might be time to get your hearing checked, writes @juliejargon. A study revealed a correlation that could affect your future well-being.
TWSJ·9h ago·3 min read